Top

Published in:

01-09-2016 | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Primary and Disseminated Cutaneous Coccidioidomycosis: Clinical Aspects and Diagnosis

Authors: Martin Arce, Daniela Gutierrez-Mendoza

Published in: Current Fungal Infection Reports | Issue 3/2016

Abstract

Coccidioidomycosis is an endemic systemic mycosis of the western hemisphere that has acquired mayor relevance after a raise in cases in the recent years. Two species, Coccidioides immitis and C. posadasii are recognized as the causative agents of this disease that, in principle, primarily affects the lungs. Extra pulmonary cutaneous forms have been more frequently reported and its manifestations present a vast clinical spectrum that resembles subcutaneous mycosis, cutaneous tuberculosis or even skin cancer. The interaction of the host and its immune response against the fungus and its pathogenic mechanism play a major role in the evolution, clinical and histopathological aspects and finally in the resolution of the disease.

Colombo AL, Tobón A, Restrepo A, et al. Epidemiology of endemic systemic fungal infections in Latin America. Med Mycol. 2011;49(8):785–98.PubMed

Benedict K, Thompson III GR, Deresinski S, Chiller T. Mycotic infections acquired outside areas of known endemicity. United States Emerg Infect Dis. 2015;21(11):1935–41. doi:10.3201/eid2111.141950.PubMedCrossRef

3.•

Blair J, Chang YH, Cheng MR, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis. 2014;20(6):983–90. doi:10.3201/eid2006.131842. Prospective study and detail description of patients with pulmonary coccidioidomycosis.PubMedPubMedCentralCrossRef

Chang A, Tung RC, McGillis TS, et al. Primary cutaneous coccidioidomycosis. J Am Acad Dermatol. 2003;49(5):944–9.PubMedCrossRef

Blair JE. State-of-the-art treatment of coccidioidomycosis skin and soft-tissue infections. Ann NY Acad Sci. 2007;1111:411–21.PubMedCrossRef

Sondermeyer G, Lee L, Gilliss D, et al. Associated-associated hospitalizations, California, USA, 2000–2011. Emerg Infect Dis. 2013;19(10):1590–7. doi:10.3201/eid1910.130427.PubMedPubMedCentralCrossRef

7.•

CDC. Increase in reported coccidioidomycosis—United States, 1998–2011. MMWR. 2013;62(12):217–21. Epidemiology report of coccidiodomycosis cases have increased dramatically in endemic areas.

Seitz AE, Prevots DR, Holland SM. Hospitalizations associated with disseminated coccidioidomycosis, Arizona and California, USA. Emerg Infect Dis. 2012;18(9):1476–9. doi:10.3201/eid1809.120151.PubMedPubMedCentralCrossRef

Crum NF, Ballon-Landa G. Coccidioidomycosis in pregnancy: case report and review of the literature. Am J Med. 2006;119(11):993. e11-7.PubMedCrossRef

10.

Marsden-Haug N, Goldoft M, Ralston C, et al. Coccidioidomycosis acquired in Washington State. Clin Infect Dis. 2013;56(6):847–50. doi:10.1093/cid/cis1028.PubMedCrossRef

11.•

Litvintseva AP, Marsden-Haug N, Hurst S, et al. Valley fever: Finding new places for an old disease: Coccidioides immitis found in Washington state soil associated with recent human infection. Clin Infect Dis. 2015;60(1):e1–3. doi:10.1093/cid/ciu681. This study demonstrates colonization of soils by C. immitis linked to human infections and located outside the endemic range.PubMedCrossRef

12.

Wilson JW. The importance of portal of entry in certain microbial infections. The primary cutaneous “chancriform syndrome”. Dis Chest; 54(S1): 299–304. http://journal.publications.chestnet.org.

13.

Deus Filho A, Deus ACB, Meneses AO, et al. Skin and mucous membrane manifestations of coccidioidomycosis: a study of thirty cases in the Brazilian states of Piauí and Maranhão. An Bras Dermatol. 2010;85(1):45–51. doi:10.1590/S0365-05962010000100006.PubMedCrossRef

14.

Simental-Lara F, Bonifaz A. Coccidioidomicosis en la región lagunera de Coahuila, México. Dermatol Rev Mex. 2011;55(3):140–51.

15.•

Moreno-Coutiño G, Arce-Ramírez M, Medina A, et al. Coccidioidomicosis cutánea. Comunicación de seis casos mexicanos. Rev Chilena Infectol. 2015;32(3):339–43. This article is one of first reports of Coccidioides posadasii infection in cutaneous coccidioidomycosis.PubMedCrossRef

16.

Salas-Alanis JC, Ocampo-Candiani J, Cepeda-Valdes R, et al. Cutaneous coccidioidomycosis: Incidental finding. J Clin Exp Dermatol Res. 2012;3:147. doi:10.4172/2155-9554.1000147.

17.

Narang V, Garg B, Sood N, Goraya SK. Primary cutaneous coccidioidomycosis: first imported case in north India. Indian J Dermatol. 2014;59:422.PubMedPubMedCentralCrossRef

18.

Kantarcioglu AS, Sandoval-Denis M, Aygun G, et al. First imported coccidiodomycosis in Turkey: a potential health risk for laboratory workers outside endemic areas. Med Mycol Case Rep. 2014;3:20–5. doi:10.1016/j.mmcr.2014.01.002.PubMedPubMedCentralCrossRef

19.

Al-Daraji WI, Al-Mahmoud RM, Ali MA. Disseminated Coccidioidomycosis: a case report from the United Kingdom. Int J Clin Exp Pathol. 2009;2:494–7. www.ijcep.com/IJCEP803007.PubMed

20.

Tortorano AM, Carminati G, Tosoni A, et al. Primary cutaneous coccidioidomycosis in an Italian nun working in South America and review of published literature. Mycopathologia. 2015;180(3-4):229–35. doi:10.1007/s11046-015-9895-0.PubMedCrossRef

21.••

Whiston E, Taylor JW. Comparative phylogenomics of pathogenic and nonpathogenic species. G3: Genes Genomes Genetics. 2016;6(2):235–44. doi:10.1534/g3.115.022806. Phylogenetic study on Coccidioides spp. gene family expansion/contraction and their metabolism.CrossRef

22.•

Nguyen C, Barker BM, Hoover S, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev. 2013;26(3):505–25. doi:10.1128/CMR.00005-13. This is a complete review of the disease.PubMedPubMedCentralCrossRef

23.

Gaidici A, Saubolle MA. Transmission of coccidioidomycosis to a human via a cat bite. J Clin Microbiol. 2009;47(2):505–6. doi:10.1128/JCM.0186008.PubMedCrossRef

24.•

Johnson L, Gaab EM, Sanchez J, et al. Valley fever: danger lurking in a dust cloud. Microbes Infect. 2014;16(8):591–600. doi:10.1016/j.micinf.2014.06.011. This is a review comprehending pathogenic aspects and host immune response.PubMedPubMedCentralCrossRef

25.

Lewis ERG, Bowers JR, Barker BM. Dust devil: the life and times of the fungus that causes valley fever. PLoS Pathog. 2015;11(5):e1004762. doi:10.1371/journal.ppat.1004762.PubMedPubMedCentralCrossRef

26.

Vinh DC, Schwartz B, Hsu AP, et al. Interleukin-12 receptor b1 deficiency predisposing to disseminated coccidioidomycosis. Clin Infect Dis. 2011;52(4):e99–102.PubMedPubMedCentralCrossRef

27.

Hung C-Y, Seshan K, Yu J, et al. A metalloproteinase of Coccidioides posadasii contributes to evasion of host detection. Infect Immune. 2005;73(10):6689–703.CrossRef

28.

Fanning S, Mitchell AP. Fungal biofilms. PLoS Pathog. 2012;8(4):e1002585. doi:10.1371/journal.ppat.1002585.PubMedPubMedCentralCrossRef

29.

Sharpton TJ, Stajich JE, Rounsley SD, et al. Comparative genomic analyses of the human fungal pathogens Coccidioides and their relatives. Genome Res. 2009;19:1722–31.PubMedCrossRefPubMedCentral

30.

Li J, Yu L, Tian Y, Zhang KQ. Molecular evolution of the deuterolysin (M35) family genes in Coccidioides. PLoS One. 2012;7(2):e31536. doi:10.1371/journal.pone.0031536.PubMedPubMedCentralCrossRef

31.

Mirbod-Donovan F, Schaller R, Hung C-Y, et al. Urease produced by Coccidioides posadasii contributes to the virulence of this respiratory pathogen. Infect Immun. 2006;74(1):504–15. doi:10.1128/IAI.74.1.504-515.2006.PubMedPubMedCentralCrossRef

32.

Wise HZ, Hung C-Y, Whiston E, Taylor JW, Cole GT. Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease. Microb Pathog. 2013;0:19–28. doi:10.1016/j.micpath.2013.04.003.PubMedCentralCrossRef

33.

Ondo AL, Zlotoff J, Mings SM, et al. Primary cutaneous coccidioidomycosis: an incidental finding. Clin Exp Dermatol. 2010;35(3):e42–3.PubMedCrossRef

34.

DiCaudo DJ. Coccidioidomycosis: a review and update. J Am Acad Dermatol. 2006;55(6):929–42.PubMedCrossRef

35.

DiCaudo DJ. Coccidioidomycosis. Semin Cutan Med Surg. 2014;33:140–5.PubMedCrossRef

36.

Garcia-Garcia SC, Salas-Alanis JC, Gomez-Flores M, et al. Coccidioidomycosis and the skin: a comprehensive review. An Bras Dermatol. 2015;90(5):610–21. doi:10.1590/abd1806-4841.20153805.PubMedCrossRef

37.

Mangold AR, DiCaudo DJ, Blair JE, Sekulic A. Chronic interstitial granulomatous dermatitis in coccidioidomycosis. Br J Dermatol. 2015; 17. doi: 10.1111/bjd.14295

38.

Garza-Chapa JI, Martínez-Cabriales SA, Ocampo-Garza J, et al. Cold subcutaneous abscesses as the first manifestation of disseminated coccidioidomycosis in an immunocompromised host. Australas J Dermatol. 2015. doi:10.1111/ajd.12424.PubMed

39.

Langelier C, Baxi SM, Iribarne D, Chin-Hong P. Beyond the superficial: Coccidioides immitis fungaemia in a man with fever, fatigue and skin nodules: a case of an emerging and evolving pathogen. BMJ Case Reports. 2014. doi:10.1136/bcr-2014-205333.PubMedCentral

40.

Carpenter JB, Feldman JS, Leyva WH, et al. Clinical and pathologic characteristics of disseminated cutaneous coccidioidomycosis. J Am Acad Dermatol. 2010;62(5):831–7.PubMedCrossRef

41.

Ocampo-Garza J, Castrejón-Pérez AD, Gonzalez-Saldivar G, et al. Cutaneous coccidioidomycosis: a great mimicker. BMJ Case Rep. 2015. doi:10.1136/bcr-2015-211680.PubMed

42.

Rodriguez R, Konia T. Coccidioidomycosis of the tongue. Arch Pathol Lab Med. 2005;129(1):e4–6.PubMed

43.

Ellerbrook L, Laks S, Cocciodioidomycosis osteomyelitis of the knee in a 23-year-old diabetic patient. Radiol Case Reports. (Online) 2014; 10(1); 1034.

44.

Jaramillo-Moreno G, Velázquez-Arenas L, Mendez-Olvera N, Ocampo-Candiani J. Primary cutaneous coccidioidomycosis: case report and review of the literature. Int J Dermatol. 2006;45:121–3. doi:10.1111/j.1365-4632.2004.02446.x.CrossRef

45.

Rojas-García OC, Moreno-Treviño MG, González-Salazar F, et al. Primary cutaneous coccidioidomycosis in an infant. Gac Med Mex. 2014;150(2):175–6.PubMed

46.

Saúl A, Bonifaz A. Clasificación de la esporotricosis. Una propuesta con base en el comportamiento inmunológico. Dermatol Rev Mex. 2011;55(4):200–8.

47.

Tchernev G, Cardoso JC, Chokoeva AA, et al. The “mystery” of cutaneous sarcoidosis: facts and controversies. Int J Immunopathol Pharmacol. 2014;27(3):321–30.PubMed

48.

Newlon HR, Lambiase MC. Disseminated cutaneous coccidioidomycosis masquerading as lupus pernio. Cutis. 2010;86(1):25–8.PubMed

49.

Crum NF. Disseminated coccidioidomycosis with cutaneous lesions clinically mimicking mycosis fungoides. Int J Dermatol. 2005;44(11):958–60.PubMedCrossRef

50.

Arora NP, Taneja V, Reyes Sacin C, et al. Coccidioidomycosis masquerading as malignancy. BMJ Case Rep. 2012. doi:10.1136/bcr.12.2011.5357.

51.

Wilson JW, Smith CE, Plunkett OA. Primary cutaneous coccidioidomycosis. The criteria for diagnosis and a report of a Case. Calif Med. 1953;79(3):233–9. PMCID: PMC1521839.PubMedPubMedCentral

52.

Pappagianis D. The phenomenon of locus minoris resistentiae in coccidioidomycosis. In: Coccidioidomycosis, Proceedings of the 4th International Conference on Coccidioidomycosis, San Diego, Calif. March, 14-17, 1984. Washington, DC: The National Foundation for Infectious Diseases; 1985:319–329.

53.

Ruocco V, Brunetti G, Puca RV, Ruocco E. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol Venereol. 2009;23(12):1364–73. doi:10.1111/j.1468-3083.2009.03345.x.PubMedCrossRef

54.

Ruocco V, Ruocco E, Piccolo V, et al. The immunocompromised district in dermatology: a unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014;32(5):569–76. doi:10.1016/j.clindermatol.2014.04.004.PubMedCrossRef

55.•

Muñoz-Hernández B, Palma-Cortés G, Carlos Cabello-Gutiérrez C, et al. Parasitic polymorphism of Coccidioides spp. BMC Infect Dis. 2014;14:213. http://www.biomedcentral.com/1471-2334/14/213 . In this study, the authors observed parasitic morphological diversity of Coccidioides in clinical samples.PubMedPubMedCentralCrossRef

56.

Kappel ST, Wu JJ, Hillman JD, et al. Histopathologic findings of disseminated coccidioidomycosis with hyphae. Arch Dermatol. 2007;143(4):548–9. doi:10.1001/archderm.143.4.548.PubMedCrossRef

57.

Ampel NM. The diagnosis of coccidioidomycosis. F1000 Med Rep. 2010;2:2. doi:10.3410/M2-2.PubMedPubMedCentral

58.

Berg N, Ryscavage P, Kulesza P. The utility of fine needle aspiration for diagnosis of extrapulmonary coccidioidomycosis: a case report and discussion. Clin Med Res. 2011;9(3-4):130–3.PubMedPubMedCentralCrossRef

59.

Aly FZ, Millis R, Sobonya R, et al. Cytologic diagnosis of coccidiodomycosis: spectrum of findings in Southern Arizona patients over a 10 year period. Diagn Cytopathol. 2016;44(3):195–200. doi:10.1002/dc.23419.PubMedCrossRef

60.

Khalbuss WE, Michelow P, Benedict C, et al. Cytomorphology of unusual infectious entities in the Pap test. Cyto J. 2012;9:15. doi:10.4103/1742-6413.97763.

61.

Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24(2):247–80. doi:10.1128/CMR.00053-10.PubMedPubMedCentralCrossRef

62.

Fernandez-Flores A, Saeb-Lima M, Arenas-Guzman R. Morphological findings of deep cutaneous fungal infections. Am J Dermatopathol. 2014;36(7):531–56.PubMedCrossRef

63.

Jehangir W, Tadepalli GS, Sen S, et al. Coccidioidomycosis and blastomycosis: endemic mycotic co-infections in the HIV patient. J Clin Med Res. 2015;7(3):196–8. doi:10.14740/jocmr2036w.PubMedCrossRef

64.

Miller JM, Astles R, Baszler T, et al. Guidelines for safe work practices in human and animal medical diagnostic laboratories. Recommendations of a CDC-convened, Biosafety Blue Ribbon Panel. MMWR. 2012;61(1):1–102.

65.

Johnson R, Kernerman SM, Sawtelle BG, et al. Reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis. Mycopathologia. 2012;174(5-6):353–8. doi:10.1007/s11046-012-9555-6.PubMedCrossRef

66.

Wack EE, Ampel NM, Sunenshine RH, Galgiani JN. The return of delayed-type hypersensitivity skin testing for coccidioidomycosis. Clin Infect Dis. 2015;61(5):787–91. doi:10.1093/cid/civ388.PubMedCrossRef

67.

Mendoza N, Blair JE. The utility of diagnostic testing for active coccidioidomycosis in solid organ transplant recipients. Am J Transplant. 2013;13(4):1034–9. doi:10.1111/ajt.12144.PubMedCrossRef

68.

Arvanitis M, Anagnostou T, Fuchs BB, et al. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490–526. doi:10.1128/CMR.00091-13.PubMedPubMedCentralCrossRef

69.••

Navalkar KA, Johnston SA, Woodbury N, et al. Application of immunosignatures for diagnosis of valley fever. Clin Vaccine Immunol. 2014;21(8):1169–77. doi:10.1128/CVI.00228-14. This is a new technology improve Coccidioidomycosis diagnosis with a higher sensitivity and it can distinguish related infections.PubMedCentralCrossRefPubMed

70.

Duarte-Escalante E, Frias-De leon MG, et al. Molecular markers in the epidemiology and diagnosis of coccidioidomycosis. Rev Iberoam Micol. 2014;31(1):49–53.PubMedCrossRef

71.

Binnicker MJ, Buckwalter SP, Eisberner JJ, et al. Detection of Coccidioides species in clinical specimens by real-time PCR. J Clin Microbiol. 2007;45(1):173–8. doi:10.1128/JCM.01776-06.PubMedCrossRef

72.

Mitchell M, Dizon D, Libke R, et al. Development of a real-time PCR assay for identification of Coccidioides immitis by use of the BD Max system. J Clin Microbiol. 2015;53(3):926–9. doi:10.1128/JCM.02731-14.PubMedPubMedCentralCrossRef

73.

Ampel NM. The treatment of coccidioidomycosis. Rev Inst Med Trop Sao Paulo. 2015;57(S19):51–6. doi:10.1590/S0036-46652015000700010.PubMedPubMedCentralCrossRef

74.

Welsh O, Vera-Cabrera L, et al. Coccidioidomycosis. Clin Dermatol. 2012;30(6):573–91.PubMedCrossRef

75.

Bercovitch RS, Catanzaro A, Schwartz BS, et al. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis. 2011;53(4):363–8. doi:10.1093/cid/cir410.PubMedCrossRef

76.

Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis. 2007;45(5):562–8.PubMedCrossRef

77.

Chang M, Chagan L. Posaconazole (Noxafil), an extended-spectrum oral triazole antifungal agent. Pharm Ther. 2008;33(7):391–426. PMC2740948.

78.

Lat A, Thompson III GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist. 2011;4:43–53. doi:10.2147/IDR.S12714.PubMedPubMedCentral

79.

Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011;53(11):1060–6. doi:10.1093/cid/cir642.PubMedCrossRef

80.

Duplessis CA, Tilley D, Bavaro M, et al. Two cases illustrating successful adjunctive interferon-g immunotherapy in refractory disseminated coccidioidomycosis. J Infect. 2011;63(3):223–8. doi:10.1016/j.jinf.2011.07.006.PubMedPubMedCentralCrossRef

Title: Primary and Disseminated Cutaneous Coccidioidomycosis: Clinical Aspects and Diagnosis
Authors: Martin Arce
Daniela Gutierrez-Mendoza
Publication date: 01-09-2016
Publisher: Springer US
Published in: Current Fungal Infection Reports / Issue 3/2016
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-016-0263-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

Diagnosis of Midwestern Endemic Mycoses

Review on Tinea Incognita

Clinical Focus on Malassezia Folliculitis

Sporotrichosis in Children: an Update

Pityriasis Versicolor: Clinical Spectrum and Diagnosis

Azole Resistance in Moulds—Approach to Detection in a Clinical Laboratory

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials